Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia

Takako Shimada, Toshiaki Saito, Masao Okadome, Kumi Shimamoto, Kazuya Ariyoshi, Takako Eto, Yui Tomita, Keisuke Kodama

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Objective: Secondary leukemia is a known complication of chemotherapy and radiotherapy. It was generally recognized that leukemia secondary to chemotherapy was due to the use of alkylating agents in the treatment of ovarian cancer. Recently, many types of chemotherapeutic agents have been used in the treatment of gynecologic malignancies in addition to ovarian cancer. We analyzed the clinical characteristics and outcome of patients with recent onset of secondary leukemia after the treatment of gynecologic cancer to consider the diagnosis and management of secondary leukemia. Materials and Methods: We reviewed the clinical charts and follow-up data of patients with gynecologic malignancies treated in the past 20 years. During this period, 2482 newly diagnosed invasive gynecologic cancers were treated in our institution. All patients with secondary leukemiawere analyzed for clinical background, latency period (interval between the diagnosis of primary carcinoma and the development of leukemia), treatment, and outcome. We also reviewed the literature for secondary leukemia under gynecology using the PubMed. Results: Four patients were found to have developed secondary leukemia after the treatment of gynecologic malignancies during this period. The cumulative risk of secondary leukemia was approximately 0.38%. All patients received platinum-based chemotherapy. Two patients received combination chemotherapy and/or bone marrow transplantation, and 1 of these 2 patients lived more than 6 years but died of recurrent ovarian cancer. Conclusions: Long survival time might be expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia. In recent years, we have aggressively used various types of anticancer drugs for the treatment of not only ovarian cancer but also uterine cervical cancer and endometrial cancer. Physicians need to keep in mind the risk of secondary leukemia in the follow-up of long-term survivors after several courses of chemotherapy and radiotherapy.

Original languageEnglish
Pages (from-to)178-183
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number2
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Leukemia
Radiotherapy
Drug Therapy
Neoplasms
Ovarian Neoplasms
Combination Drug Therapy
Bone Marrow Transplantation
Therapeutics
Alkylating Agents
Endometrial Neoplasms
Platinum
Gynecology
PubMed
Uterine Cervical Neoplasms
Survivors
Carcinoma
Physicians
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Shimada, T., Saito, T., Okadome, M., Shimamoto, K., Ariyoshi, K., Eto, T., ... Kodama, K. (2014). Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia. International Journal of Gynecological Cancer, 24(2), 178-183. https://doi.org/10.1097/IGC.0000000000000045

Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia. / Shimada, Takako; Saito, Toshiaki; Okadome, Masao; Shimamoto, Kumi; Ariyoshi, Kazuya; Eto, Takako; Tomita, Yui; Kodama, Keisuke.

In: International Journal of Gynecological Cancer, Vol. 24, No. 2, 01.2014, p. 178-183.

Research output: Contribution to journalReview article

Shimada, T, Saito, T, Okadome, M, Shimamoto, K, Ariyoshi, K, Eto, T, Tomita, Y & Kodama, K 2014, 'Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia', International Journal of Gynecological Cancer, vol. 24, no. 2, pp. 178-183. https://doi.org/10.1097/IGC.0000000000000045
Shimada, Takako ; Saito, Toshiaki ; Okadome, Masao ; Shimamoto, Kumi ; Ariyoshi, Kazuya ; Eto, Takako ; Tomita, Yui ; Kodama, Keisuke. / Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 2. pp. 178-183.
@article{41ee91a75ddf4ed7a3e10e797b257dbd,
title = "Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia",
abstract = "Objective: Secondary leukemia is a known complication of chemotherapy and radiotherapy. It was generally recognized that leukemia secondary to chemotherapy was due to the use of alkylating agents in the treatment of ovarian cancer. Recently, many types of chemotherapeutic agents have been used in the treatment of gynecologic malignancies in addition to ovarian cancer. We analyzed the clinical characteristics and outcome of patients with recent onset of secondary leukemia after the treatment of gynecologic cancer to consider the diagnosis and management of secondary leukemia. Materials and Methods: We reviewed the clinical charts and follow-up data of patients with gynecologic malignancies treated in the past 20 years. During this period, 2482 newly diagnosed invasive gynecologic cancers were treated in our institution. All patients with secondary leukemiawere analyzed for clinical background, latency period (interval between the diagnosis of primary carcinoma and the development of leukemia), treatment, and outcome. We also reviewed the literature for secondary leukemia under gynecology using the PubMed. Results: Four patients were found to have developed secondary leukemia after the treatment of gynecologic malignancies during this period. The cumulative risk of secondary leukemia was approximately 0.38{\%}. All patients received platinum-based chemotherapy. Two patients received combination chemotherapy and/or bone marrow transplantation, and 1 of these 2 patients lived more than 6 years but died of recurrent ovarian cancer. Conclusions: Long survival time might be expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia. In recent years, we have aggressively used various types of anticancer drugs for the treatment of not only ovarian cancer but also uterine cervical cancer and endometrial cancer. Physicians need to keep in mind the risk of secondary leukemia in the follow-up of long-term survivors after several courses of chemotherapy and radiotherapy.",
author = "Takako Shimada and Toshiaki Saito and Masao Okadome and Kumi Shimamoto and Kazuya Ariyoshi and Takako Eto and Yui Tomita and Keisuke Kodama",
year = "2014",
month = "1",
doi = "10.1097/IGC.0000000000000045",
language = "English",
volume = "24",
pages = "178--183",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Secondary leukemia after chemotherapy and/or radiotherapy for gynecologic neoplasia

AU - Shimada, Takako

AU - Saito, Toshiaki

AU - Okadome, Masao

AU - Shimamoto, Kumi

AU - Ariyoshi, Kazuya

AU - Eto, Takako

AU - Tomita, Yui

AU - Kodama, Keisuke

PY - 2014/1

Y1 - 2014/1

N2 - Objective: Secondary leukemia is a known complication of chemotherapy and radiotherapy. It was generally recognized that leukemia secondary to chemotherapy was due to the use of alkylating agents in the treatment of ovarian cancer. Recently, many types of chemotherapeutic agents have been used in the treatment of gynecologic malignancies in addition to ovarian cancer. We analyzed the clinical characteristics and outcome of patients with recent onset of secondary leukemia after the treatment of gynecologic cancer to consider the diagnosis and management of secondary leukemia. Materials and Methods: We reviewed the clinical charts and follow-up data of patients with gynecologic malignancies treated in the past 20 years. During this period, 2482 newly diagnosed invasive gynecologic cancers were treated in our institution. All patients with secondary leukemiawere analyzed for clinical background, latency period (interval between the diagnosis of primary carcinoma and the development of leukemia), treatment, and outcome. We also reviewed the literature for secondary leukemia under gynecology using the PubMed. Results: Four patients were found to have developed secondary leukemia after the treatment of gynecologic malignancies during this period. The cumulative risk of secondary leukemia was approximately 0.38%. All patients received platinum-based chemotherapy. Two patients received combination chemotherapy and/or bone marrow transplantation, and 1 of these 2 patients lived more than 6 years but died of recurrent ovarian cancer. Conclusions: Long survival time might be expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia. In recent years, we have aggressively used various types of anticancer drugs for the treatment of not only ovarian cancer but also uterine cervical cancer and endometrial cancer. Physicians need to keep in mind the risk of secondary leukemia in the follow-up of long-term survivors after several courses of chemotherapy and radiotherapy.

AB - Objective: Secondary leukemia is a known complication of chemotherapy and radiotherapy. It was generally recognized that leukemia secondary to chemotherapy was due to the use of alkylating agents in the treatment of ovarian cancer. Recently, many types of chemotherapeutic agents have been used in the treatment of gynecologic malignancies in addition to ovarian cancer. We analyzed the clinical characteristics and outcome of patients with recent onset of secondary leukemia after the treatment of gynecologic cancer to consider the diagnosis and management of secondary leukemia. Materials and Methods: We reviewed the clinical charts and follow-up data of patients with gynecologic malignancies treated in the past 20 years. During this period, 2482 newly diagnosed invasive gynecologic cancers were treated in our institution. All patients with secondary leukemiawere analyzed for clinical background, latency period (interval between the diagnosis of primary carcinoma and the development of leukemia), treatment, and outcome. We also reviewed the literature for secondary leukemia under gynecology using the PubMed. Results: Four patients were found to have developed secondary leukemia after the treatment of gynecologic malignancies during this period. The cumulative risk of secondary leukemia was approximately 0.38%. All patients received platinum-based chemotherapy. Two patients received combination chemotherapy and/or bone marrow transplantation, and 1 of these 2 patients lived more than 6 years but died of recurrent ovarian cancer. Conclusions: Long survival time might be expected in patients who show complete response to bone marrow transplantation and/or combination chemotherapy for secondary leukemia. In recent years, we have aggressively used various types of anticancer drugs for the treatment of not only ovarian cancer but also uterine cervical cancer and endometrial cancer. Physicians need to keep in mind the risk of secondary leukemia in the follow-up of long-term survivors after several courses of chemotherapy and radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84893741227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893741227&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000045

DO - 10.1097/IGC.0000000000000045

M3 - Review article

C2 - 24407580

AN - SCOPUS:84893741227

VL - 24

SP - 178

EP - 183

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -